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OBJECTIVE — The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study found
strong associations between higher levels of maternal glucose at 24–32 weeks, within what is
currentlyconsiderednormoglycemiaandadversepregnancyoutcomes.Ouraimwastoevaluate
the associations between ﬁrst-trimester fasting plasma glucose level and adverse pregnancy
outcomes.
RESEARCH DESIGN AND METHODS — Charts of all patients who delivered at our
hospital between June 2001 and June 2006 were reviewed. Only subjects with singleton preg-
nancy and a recorded ﬁrst-trimester fasting glucose level were included. Women with preges-
tational diabetes, fasting glucose level 105 mg/dl, or delivery 24 weeks were excluded.
Fasting glucose levels were analyzed in seven categories, similar to the HAPO study. The main
outcomes were development of gestational diabetes mellitus (GDM), large-for-gestational-age
(LGA) neonates and/or macrosomia, and primary cesarean section. Multivariate logistic regres-
sion analysis was used; signiﬁcance was 0.05.
RESULTS — A total of 6,129 women had a fasting glucose test at median of 9.5 weeks. There
were strong, graded associations between fasting glucose level and primary outcomes. The
frequencyofGDMdevelopmentincreasedfrom1.0%inthelowestglucosecategoryto11.7%in
the highest (adjusted odds ratio 11.92 [95% CI 5.39–26.37]). The frequency of LGA neonates
and/or macrosomia increased from 7.9 to 19.4% (2.82 [1.67–4.76]). Primary cesarean section
rate increased from 12.7 to 20.0% (1.94 [1.11–3.41]).
CONCLUSIONS — Higher ﬁrst-trimester fasting glucose levels, within what is currently
consideredanondiabeticrange,increasetheriskofadversepregnancyoutcomes.Earlydetection
andtreatmentofwomenathighriskforthesecomplicationsmightimprovepregnancyoutcome.
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W
omen with gestational diabetes
mellitus (GDM) are at increased
risk for adverse perinatal and
maternal outcomes, including macroso-
mia, cesarean section, birth trauma, and
later diabetes. The Toronto Tri-Hospital
Gestational Diabetes Project (1) and the
Hyperglycemia and Adverse Pregnancy
Outcome (HAPO) Research Group (2)
studied the relationship between plasma
glucose levels, less severe than overt
GDM, and pregnancy outcomes. They
found graded relation between increasing
levels of fasting, 1-h, and 2-h plasma glu-
cose obtained on oral glucose tolerance
testingat24–32weeksandawidevariety
of adverse pregnancy outcomes, includ-
ingincreasedbirthweight,primarycesar-
ean section, neonatal hypoglycemia, and
precclampsia.
Using fasting plasma glucose as a
screening test for adverse pregnancy out-
comes early in gestation offers some
advantages compared with glucose chal-
lenge tests (GCTs). Glucose tolerance
tests are poorly reproducible, are time
consuming and expensive, require exten-
sivepatientpreparation,areinconvenient
to administer, and are unpleasant for the
patient,andinpregnantwomenvomiting
is a common problem. Fasting plasma
glucose is easy to administer, well toler-
ated, inexpensive, reliable, reproducible,
and has been reported to vary little
throughout gestation (3). However, there
isnouniversallyagreeddeﬁnitionfornor-
mal fasting glucose level in pregnancy. In
pregnant women, similar to the nonpreg-
nant state, fasting plasma glucose 125
mg/dl is considered diagnostic for diabe-
tes (4). In nonpregnant adults, impaired
fasting glucose is diagnosed with fasting
glucose levels of 100–125 mg/dl (4).
However, there is no deﬁnition for im-
paired fasting glucose during pregnancy:
in the 3-h 100-g oral glucose tolerance
test(OGTT),afastingglucosevalue105
mg/dl was considered abnormal by the
National Diabetes Data Group’s criteria
(5), whereas the Carpenter and Coustan
criteria (6) for the diagnosis of GDM set
the normal fasting glucose, in the OGTT,
to 95 mg/dl.
Detection of women at higher risk for
adverse pregnancy outcomes early in
pregnancy is a desirable goal because in-
terventions such as diet, medication, and
exercisemaybeappliedearlierandhavea
positive effect on maternal and fetal out-
comes (7–9). Therefore, we wanted to
evaluate, retrospectively, the associations
between fasting glucose level in the ﬁrst
trimester within what is currently consid-
ered normoglycemia and adverse preg-
nancy outcomes.
RESEARCH DESIGN AND
METHODS— The protocol was ap-
proved by the institutional review board
for human investigation at The Lady
Davis Carmel Medical Center, which is
part of Clalit HMO. The study was also
approved, for computerized laboratory
dataretrieval,bythecommitteeforhealth
policy research in the central administra-
tion of Clalit HMO. This was a retrospec-
tive study on deliveries that took place in
Carmel Lady Davis Hospital from June
2001 to June 2006. During this period,
we used a computerized medical record
in the labor-and-delivery ward. The com-
puterized record includes demographic
data (including woman’s name, identiﬁ-
cation number, age, and maternal self-
report of prepregnancy weight and
height), obstetric data (including gravity,
parity, previous cesarean section, and es-
timated last menstrual period based on
both date of last menstrual period and
early ultrasound examination), delivery
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and mode of delivery), and neonatal data
(including neonatal weight and Apgar
score). These data were extracted into a
computerized database (Access; Mi-
crosoft, Seattle, WA).
There is no uniform worldwide
guidelines for screening and diagnosis of
GDM (10). In Israel, the Ministry of
Health recommends universal testing for
fasting glucose level at the ﬁrst prenatal
care visit and a universal 50-g GCT at
24–28weeksofgestation(11).According
to these guidelines, women with abnor-
mal GCT of 140 mg/dl should undergo
a 3-h 100-g OGTT.
The Israeli National Health Insurance
Law provides universal health services to
every resident. Carmel Lady Davis Hospi-
tal is part of the Clalit Health Services,
which is the largest HMO in Israel. Using
the unique identity number assigned to
all Israeli residents and through the cen-
tral laboratory computer of the Clalit
HMO, we extracted the results of all glu-
cosebloodteststhatweredoneduringthe
study period for patients who gave birth
inourhospitalandhadClalitHMOinsur-
ance. Gestational age for the various glu-
cose tests was calculated using the date of
last menstrual period and the date of glu-
cose test. Venous plasma glucose concen-
tration was determined by the glucose
oxidase method in Clalit laboratories.
Only subjects with singleton pregnancy
and a recorded ﬁrst-trimester fasting glu-
cose level were included in this study.
Womenwithpregestationaldiabetesmel-
litus,fastingglucoselevel105mg/dl,or
delivery at 24 weeks of gestation were
excluded.
Large for gestational age (LGA), de-
ﬁnedasneonatalbirthweight90thper-
centile for gestational age and sex, was
determinedaccordingtothepublishedIs-
raelibirthweightstandard(12).Macroso-
mia was deﬁned as birth weight 4,000
g. GDM was diagnosed when an abnor-
mal GCT (140 mg/dl) was followed by
two or more abnormal values on a 3-h
(100-g) glucose tolerance test using the
Carpenter and Coustan criteria (6). GDM
was also diagnosed with a GCT value of
200 mg/dl.
The main outcomes were the devel-
opment of GDM, LGA and/or macroso-
mia, and primary cesarean delivery.
Secondary outcomes were premature de-
livery before 37 weeks of gestation and
admission to the neonatal intensive care
unit. We also analyzed the correlation be-
tween ﬁrst-trimester fasting glucose level
and that of GCT and OGTT.
Fasting glucose levels were analyzed
in seven categories (75, 75–79, 80–84,
85–89,90–94,95–99,and100–105mg/
dl), similar to the HAPO study (2). Data
were tested for normal distribution (Kol-
mogorov-Smirnov test). Pearson correla-
tion test and multivariate logistic
regression analysis were conducted in
SigmaStat version 2.03 and Minitab ver-
sion 12.23. Statistical signiﬁcance was set
at P  0.05.
RESULTS— Of 14,550 singleton de-
liveries at 24 weeks of gestation, 7,126
women were enrollees of Clalit Health
Care Services. A total of 145 (2.0%) were
excluded because they had pregestational
diabetes or a ﬁrst-trimester fasting glu-
cose level of 105 mg/dl. A total of 852
(12%) were excluded because they had a
recorded fasting glucose level after the
ﬁrst trimester or prior to pregnancy.
Among the 852 women who did not have
a ﬁrst-trimester fasting glucose level and
thosewhohadit,themedianmaternalage
was 28.7 vs. 29.3 years, neonatal weight
was3,269vs.3,246g,andtherateofLGA
and/or macrosomia was 10.8 vs. 10.3%,
respectively.
The characteristics of the mothers,
newborns, and pregnancy outcomes are
summarized in Table 1. The median fast-
ingglucoselevelwas79mg/dlatamedian
of 9.5 weeks of gestation. More than 95%
of women had a GCT done at a median
gestationalageof24.8weeks;781women
had a conﬁrmatory 100-g OGTT at a me-
diangestationalageof26.7weeks.Atotal
of 634 (or 10.3%) of neonates were LGA
and/or macrosomic, and 173 (2.8%) of
women developed GDM. A total of 5,679
women did not have a prior cesarean sec-
tion,843(14.8%)ofwhomhadaprimary
cesareandelivery.Atotalof436deliveries
occurred prior to 37 weeks of gestation,
and 317 neonates were admitted to the
neonatal intensive care unit.
The frequency of each primary out-
come across the seven glucose categories
isshowninFig.1.Withincreasingfasting
maternal glucose levels, the frequency of
GDM development increased from 1.0%
in the lowest category to 11.7% in the
highest; the frequency of LGA and/or
macrosomiaincreasedfrom7.9to19.4%,
and for primary cesarean section it in-
creased from 12.7 to 20.0%.
Table 2 shows the associations of ma-
ternalfastingglucoseasacategoricalvari-
able with each primary outcome,
including adjusted odds ratios (AORs)
and 95% CIs for each category, as com-
pared with the lowest glucose category.
There was strong association between the
development of GDM and ﬁrst-trimester
maternal fasting glycemia, with the asso-
ciation increasing with increasing fasting
glycemia category (AOR 11.92 [95% CI
5.39–26.37] for the highest category of
fasting plasma glucose). There was also
strong association with LGA and/or mac-
rosomia, which increased across the in-
creasing fasting glycemia categories
(Table 2). This association was main-
Table 1—Characteristics of women, newborns and frequency of pregnancy outcomes
Median
(interquartile range) n (%)
Maternal and neonatal characteristics
Parity 1 (0–2) 6,096 (99.5)
Maternal age (years) 29.4 (26.2–33.1) 6,129 (100)
Neonatal birth weight (g) 3,246 (2,924–3,552) 6,128 (100)
Gestational age at delivery (weeks) 39.7 (38.6–40.6) 6,129 (100)
Gestational age at fasting glucose
(weeks)
9.5 (7.6–11.6) 6,129 (100)
Fasting glucose level (mg/dl) 79 (75–85) 6,129 (100)
Gestational age at GCT (weeks) 24.8 (24.1–25.9) 5,827 (95.1)
GCT (mg/dl) 100 (83–121) 5,827 (95.1)
Maternal and neonatal outcomes Percent n with outcomes
LGA and or macrosomia 10.3 634
GDM 2.8 173
Primary cesarean delivery* 14.8 843
Preterm delivery (37 weeks) 7.1 436
Neonatal intensive care unit admission 5.2 317
*There were 5,679 women without previous cesarean section.
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ing the women who developed GDM
(1.51 [1.18–1.95] for fasting glucose
level 80–84 mg/dl and it increased to
2.41 [1.35–4.29] in the highest category
of the fasting plasma glucose compared
with the lowest glucose category [P 
0.0001]). The AOR for primary cesarean
section increased across categories of ma-
ternal glycemia and was 1.94 in the high-
est category of fasting plasma glucose.
This association was no longer signiﬁcant
after the exclusion of women with GDM.
BMI is a known confounding factor
for GDM risk. Thus, we performed a sub-
groupanalysisincluding4,876womenin
whom we had pregestational BMI data.
After controlling for BMI, maternal age,
and parity, there was similar strong,
gradedassociationbetweenﬁrst-trimester
fasting glucose level and GDM, with the
association increasing with increasing fast-
ing glycemia category (AOR 2.01 [95% CI
1.02–4.05] for fasting glucose level 80–84
mg/dlanditincreasedto9.49[3.87–23.26]
in the highest category of fasting plasma
glucose compared with the lowest glucose
category [P  0.0001]).
We also found a strong, graded asso-
ciationbetweenﬁrst-trimesterfastingglu-
coselevelandabnormalGCT(GCT140
mg/dl), with the association increasing
with increasing fasting glycemia category
(AORincreasedfrom1.86[95%CI1.41–
2.45] in the lowest glucose category to
6.85[4.08–11.48]inthehighestcategory
of the fasting plasma glucose [P 
0.0001]). A total of 781 women had an
OGTT. There was fair correlation be-
tween ﬁrst-trimester fasting glucose level
and the fasting glucose at the time of
OGTT (Pearson correlation coefﬁcient
0.365, P  0.0001).
Therewerenosigniﬁcantassociations
between fasting glucose level category
andeitherpretermdelivery37weeksof
gestation or neonatal intensive care unit
admission(OR0.73–1.35[95%CIacross
one and P  0.1 in all fasting glucose cat-
egories for both preterm delivery and
neonatal intensive care unit admissions]).
Importantly, there was no clear threshold
for fasting glucose level that puts preg-
nant women at a signiﬁcantly increased
risk for adverse pregnancy outcome.
CONCLUSIONS — Our results indi-
cate associations between fasting ﬁrst-
trimester maternal plasma glucose level,
below those diagnostic of diabetes, and
adverse pregnancy outcome including
development of GDM, LGA and/or mac-
rosomia, and primary cesarean delivery.
GDM risk remained almost unchanged
even after controlling for pregestational
BMI, and the risk for LGA and/or macro-
somia was maintained even after exclud-
ing women with GDM. We also found a
strong, graded association between ﬁrst-
trimester fasting glucose level and abnor-
mal GCT and fair correlation between
ﬁrst-trimester fasting glucose level and
the fasting glucose at the time of OGTT.
Traditionally, GDM screen is recom-
mended in the beginning of the third tri-
mester in order to maximize the
metabolic effects of pregnancy. However,
many protocols for GDM screening use a
two-stepprocess,thusleavingonlyabrief
windowforimplementingtherapeuticin-
terventions designed to improve out-
come. The beneﬁts of screening for and
treating GDM have been a matter of con-
siderable debate (13). Advocates point to
an association of GDM with maternal and
neonatal morbidity. Critics argue that
Figure 1—The relationship between maternal ﬁrst-trimester fasting glucose level and frequency
of primary outcomes. Fasting glucose categories are deﬁned as follows: category 1, 75 mg/dl;
category 2, 75–79 mg/dl; category 3, 80–84 mg/dl; category 4, 85–89 mg/dl; category 5, 90–94
mg/dl; category 6, 95–99 mg/dl; and category 7, 100–105 mg/dl.
Table 2—AORs for associations between maternal glucose as a categorical variable and primary outcomes*
Fasting glucose n (%)
GDM n (%
outcome)
GDM
OR (95% CI)
LGA and/or
macrosomia n
(% outcome)
LGA and/or
macrosomia
OR (95% CI)
Primary cesarean
section
n (% outcome)
Primary cesarean
section
OR (95% CI)†
1 75 mg/dl 1,525 (24.9) 15 (1.0) 1.0 120 (7.9) 1.0 182 (12.7) 1.0
2 75–79 mg/dl 1,587 (25.9) 31 (2.0) 1.95 (1.05–3.62) 134 (8.4) 1.08 (0.84–1.40) 222 (14.9) 1.21 (0.98–1.5)
3 80–84 mg/dl 1,427 (23.3) 34 (2.4) 2.39 (1.30–4.42) 168 (11.8) 1.56 (1.22–2.00) 195 (14.8) 1.22 (0.98–1.52)
4 85–89 mg/dl 893 (14.6) 27 (3.0) 3.04 (1.60–5.75) 100 (11.2) 1.48 (1.12–1.95) 141 (17.0) 1.43 (1.12–1.82)
5 90–94 mg/dl 415 (6.8) 39 (9.4) 9.32 (5.07–17.14) 61 (14.7) 2.02 (1.45–2.80) 58 (15.9) 1.45 (1.04–2.00)
6 95–99 mg/dl 179 (2.9) 15 (8.4) 8.63 (4.13–18.04) 31 (17.3) 2.45 (1.60–3.77) 28 (17.3) 1.56 (1.00–2.42)
7 100–105 mg/dl 103 (1.7) 12 (11.7) 11.92 (5.39–26.37) 20 (19.4) 2.82 (1.67–4.76) 17 (20.0) 1.94 (1.11–3.41)
*Associations were adjusted for parity and maternal age. †Data for women who had a previous cesarean section were excluded.
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potential adverse outcomes are markedly
improved by diagnosis and treatment.
One potential explanation for past difﬁ-
culty in identifying a beneﬁt from screen-
ing for and treating GDM is that such
screening as typically implemented does
notoccuruntilthethirdtrimester,apoint
late in pregnancy, thus allowing only a
brief period for intervention. Indeed,
20% of fetuses already had signs of
macrosomia (abdominal circumference
above the 90% percentile in ultrasound
exam) at the time the women were ﬁrst
referred for GDM treatment (14). Several
recent studies (15–17) provide contem-
porary evidence that screening for and
treating GDM is beneﬁcial, and this evi-
dence has bolstered the arguments of
those who favor universal GDM testing.
Nevertheless, outcomes found in the
treatment arms of these studies as well as
thoseobservedingeneralclinicalpractice
suggest that there is room for improve-
ment even within the recommended test-
ing paradigm. Earlier detection of women
at risk for GDM might allow earlier inter-
vention,inordertoreduceeitherthelater
diagnosis of GDM or its associated mor-
bidities. For example, ﬁrst-trimester test-
ingandidentiﬁcationofhigh-riskwomen
allow proper diet and exercise guidance
from the beginning of the second trimes-
ter, at a time when the vomiting period
ends and usually the women’s appetite is
greatly increased. Such guidance from
early pregnancy might reduce the rate of
excessive weight gain that greatly in-
creases the risk of pregnancy complica-
tions including macrosomia, cesarean
section, shoulder dystocia, etc. (18–21).
GDM is similar to type 2 diabetes in
many aspects including treatment. It is
well documented that we can prevent or
delay the development of type 2 diabetes
in nonpregnant populations at risk for
type 2 diabetes by lifestyle intervention,
including diet modiﬁcation, weight re-
duction, and exercise (22). It is thus pos-
sible that earlier recognition of women at
risk for the development of GDM and
other adverse pregnancy outcomes might
beneﬁt from earlier detection and inter-
vention. Indeed, a small study (9) found
that ﬁrst-trimester screening and therapy
in women at high risk for GDM result in
appropriate-for-gestational-age new-
borns. Another study (7) has showed that
early glucose tolerance screening could
prevent some diabetes-related complica-
tions in women with GDM. Also, several
large population studies (18–21) found
that excessive weight gain during preg-
nancy,especiallyinoverweightandobese
pregnant women, greatly increases their
risksforadversepregnancyoutcomes,in-
cluding LGA infants and cesarean deliv-
ery. Furthermore, recreational physical
activity performed before and/or during
pregnancyisassociatedwithareducedrisk
of GDM (23). Physically active women are
also less likely to develop preeclampsia and
excessive gestational weight gain (24).
In the current study, we found that
higher ﬁrst-trimester fasting plasma glu-
cose levels, below those diagnostic of di-
abetes, were associated with higher risk
forGDMdevelopmentlaterinpregnancy.
Interestingly, a large observational study
amongyoungmenhavefoundthathigher
fasting plasma glucose levels, within the
normoglycemic range (i.e., 100 mg/dl),
constitute an independent risk factor for
thedevelopmentoftype2diabeteswithin
a few years (25).
Our results for ﬁrst-trimester fasting
glucose level are similar to the HAPO
study; for example, in the HAPO study a
fasting glucose level of 90 mg/dl was
foundin11.9%ofpregnantwomeninthe
beginning of the third trimester. This cut-
off detected 22.1% of LGA neonates and
15.1% of primary cesarean deliveries. In
the current study, fasting glucose level of
90 mg/dl was found in 11.4% of preg-
nant women during the ﬁrst trimester. It
identiﬁed17.7%ofLGAneonates,12.2%
of women who had a primary cesarean
delivery, and 38.1% of women who later
developed GDM.
First-trimester screening by fasting
glucose level also offers the opportunity
to detect and treat undiagnosed pregesta-
tional diabetes, which becomes a major
problem as the prevalence of diabetes in-
creases rapidly. Otherwise, these high-
risk women would not receive any special
treatment until the beginning of the third
trimester. Also, unrecognized and un-
treated pregestational diabetes has in-
creased risk for congenital malformations,
intrauterine fetal deaths, etc., that would
not get appropriate attention if the diag-
nosis was not made in early pregnancy.
There are several limitations to our
study. Due to the retrospective nature of
the study, we cannot be sure that all the
glucose tests were done as they should
(i.e., after appropriate fasting or after the
appropriate GCT). The 12% of women
who did not have a recorded fasting glu-
cose test during the ﬁrst trimester were
excluded. We believe that this is unlikely
tomateriallyaffectourresultsbecausethe
differences in maternal age, neonatal
weight, and LGA rate were small between
those who had a ﬁrst-trimester fasting
glucoseandthosewhodidnot.GDMdata
are somewhat incomplete given that only
95.1% of women had a GCT and 9% of
women with an abnormal GCT did not
have a diagnostic 100-g OGTT; however,
itisunlikelythatthismighthavechanged
the results substantially. Our analysis was
restricted to women who are insured by
the Clalit HMO. The Israeli National
Health Insurance Law provides universal
health services to every resident at the
same cost. Thus, it is unlikely that this
had a signiﬁcant bias on our results. The
study was conducted in a single center,
and this might inﬂuence the results,
mainly in regard to mode of delivery and
neonatal intensive care unit admission;
however,themainoutcomesofthestudy,
LGA risk and the development of GDM,
are not inﬂuenced by hospital policy.
Also, because it is a single-center study,
we cannot be sure about the relevance of
the study in other parts of the world.
Some confounders, such as previous
GDM or previous macrosomia, may have
inﬂuenced clinical decisions such as the
choice of route of delivery.
In conclusion, we found that fasting
ﬁrst-trimester glucose level lower than
what is considered impaired fasting glu-
coseinthenonpregnantstateisassociated
with adverse pregnancy outcome. It may
help identify and treat, early in preg-
nancy, apparently healthy women in or-
der to improve pregnancy outcome. A
large, prospective multicenter study on
maternalandneonataloutcomeisneeded
to better evaluate the association of ﬁrst-
trimester fasting glucose levels and the
usefulness of timely interventions on
pregnancy outcome.
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